Protara Therapeutics (TARA) EBITDA (2013 - 2026)

Protara Therapeutics' EBITDA history runs 14 years deep, the most recent figure standing at -$18.2 million for Q1 2026.

• In Q1 2026, EBITDA fell 54.19% year-over-year to -$18.2 million; the TTM figure through Mar 2026 stood at -$63.8 million (down 40.67% YoY), while the FY2025 annual figure was -$57.4 million, down 28.7% from the prior year.
• EBITDA was -$18.2 million for Q1 2026 at Protara Therapeutics, down from -$17.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$7.7 million in Q3 2022 to a low of -$38.5 million in Q4 2022.
• Historically, EBITDA has averaged -$13.3 million across 5 years, with a median of -$11.2 million in 2024.
• The sharpest annual moves came in 2022 and 2023: EBITDA sank 270.43% in 2022, then jumped 73.82% in 2023.
• A 5-year view of EBITDA shows it stood at -$38.5 million in 2022, then surged by 73.82% to -$10.1 million in 2023, then decreased by 26.86% to -$12.8 million in 2024, then slumped by 35.67% to -$17.4 million in 2025, then fell by 5.05% to -$18.2 million in 2026.
• The last three EBITDA figures came in at -$18.2 million (Q1 2026), -$17.4 million (Q4 2025), and -$13.2 million (Q3 2025), per Business Quant data.